Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$191.51 - $216.16 $66,453 - $75,007
347 Added 0.69%
50,900 $10.8 Million
Q2 2023

Jul 21, 2023

BUY
$187.64 - $206.25 $3.06 Million - $3.36 Million
16,283 Added 47.51%
50,553 $9.73 Million
Q1 2023

Apr 26, 2023

BUY
$127.59 - $203.08 $3.12 Million - $4.97 Million
24,475 Added 249.87%
34,270 $6.94 Million
Q4 2022

Jan 31, 2023

SELL
$117.37 - $139.17 $67,605 - $80,161
-576 Reduced 5.55%
9,795 $1.26 Million
Q3 2022

Oct 28, 2022

BUY
$135.27 - $180.11 $1.4 Million - $1.87 Million
10,371 New
10,371 $1.42 Million
Q1 2022

May 04, 2022

SELL
$119.61 - $157.85 $221,517 - $292,338
-1,852 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$142.57 - $190.86 $8,696 - $11,642
-61 Reduced 3.19%
1,852 $286,000
Q2 2021

Jul 21, 2021

BUY
$135.08 - $161.1 $258,408 - $308,184
1,913 New
1,913 $302,000

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Ifg Advisory, LLC Portfolio

Follow Ifg Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifg Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ifg Advisory, LLC with notifications on news.